No Detail Found!

Role of different therapeutic systems to reduce the risk of cardiovascular complications by intervening type II diabetes

Author(s)
Mahmood Sheikh Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Pakistan
Sheikh Abdul Khaliq Faculty of Pharmacy, Hamdard University, Karachi, Pakistan
Iqbal Azhar Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Pakistan
Anab Fatima Dow University of Health Sciences, Karachi, Pakistan
Abstract
Objective: To assess the risk-reduction of cardiovascular complications in patients of type-II diabetes through standardized tools of evidenced-basedmedicine. Methodology: This cross-sectional observational study was conducted at outpatient care-centers. The study included 200 patients and duration was July-2019 to June-2020. For the treatment of type-II diabetes, patients have taken either allopathic, herbal, homeopathic and/or combination systems of medicine. Endpoints of study were any cardiovascular-outcome; myocardial-infarction, hypertension, angina-pectoris, heart-failure, stroke, thrombo-embolism, coronaryartery disease, cardiac-arrhythmia. Results: Relative-risk-reduction (RRR) of cardiovascular complications as per treatment duration <1 years allopathic system v/s homoeopathic: 62.12%, Number-Needed-to-Treat (NNT)˜5.0; RRR in 5.10-7.0 years allopathic system v/s herbal: 54%, NNT˜2.0; RRR in 7.10-10.0 years allopathic system v/s herbal: 30%, NNT≈7.0; allopathic-system v/s combination: 50%, NNT≈3.0; RRR in 10.10-15.0 years allopathic system v/s combination: 24%, NNT≈8.0; RRR in 15.10 20.0 years allopathic-system v/s combination: 16%, NNT≈6.0; RRR in 20.10-25.0 years allopathic-system v/s combination: 67%, NNT≈2.0. Patients took diet of low-calorie; RRR by allopathic-system v/s combi nation: 1.25%, NNT≈222. In combination systems; RRR by allopathic herbal system v/s allopathic homoeopathic: 49.36%, NNT≈7. Conclusion: In short-term treatment (<5 years), risk reduction of cardiovascular complications was better with alternative medicines compared to allopathic system. However, in long-term treatment (>5 years), risk-reduction of cardiovascular complications was better in allopathic-system compared to alternative system of medicine.
Publication Details
Page(s) 528-533
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 49, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Diabetes Mellitus, cardiovascular, number-needed-to-treat, chronic complications, relative-risk-reduction.
References
Cardoso C,Leite N,Moram C .2018 .Salles G. Long-term visitto-visit glycemic variability as predictor of micro-and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol, 17 : 1-16.
Kostov K. .2021 .The causal relationship between endothelin-1 and hypertension: Focusing on endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure regulation. Life, 11 : 01-16.
Schalkwijk C .2020 .Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. Physiol Rev, 100 : 407-61.
Jenkins AJ,Scott E,Fulcher J,Kilov G,Januszewski AS,Cannon C .2019 .Management of diabetes mellitus. Comprehensive Cardiovascular Medicine in the Primary Care Setting:, : 113-77.
Paul S,Ali A,Katare R .2020 .Molecular complexities underlying the vascular complications of diabetes mellitus-A comprehensive review. JDC, 34 : 107613-24.
Itabe H,Kato R,Sawada N,Obama T,Yamamoto M. .2019 .The significance of oxidized low-density lipoprotein in body fluids as a marker related to diseased conditions. Curr Med Chem, 26 : 1576-93.
Robinson NA,Loynachan AT,Zimmerman JJ,Karriker LA,Ramirez A,Schwartz KJ,Stevenson GW,Zhang J .2019 .Cardiovascular and hematopoietic systems. Diseases of swine. 11th ed. Pondicherry, : 221-33.
Farah C,Michel LY,Balligand J-L .2018 .Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol, 15 : 292-316.
Patel TP,Rawal K,Bagchi AK,Akolkar G,Bernardes N,Dias DD .2016 .Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev, 21 : 11-23.
Gnatiuc L,Herrington WG,Halsey J,Tuomilehto J,Fang X,Kim HC .2018 .Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. Lancet Diabet Endocrinol, 6 : 538-46.
Sen S,Chakraborty R .2017 .Revival, modernization and integration of Indian traditional herbal medicine in clinical practice: Importance, challenges and future. J Tradit Complement Med, 7 : 234-44.
Bukhsh A,Gan SH,Goh B-H .2018 .Complementary and alternative medicine practices among type 2 diabetes patients in Pakistan: A qualitative insight. Eur J Integr Med, 23 : 43-9.
Aparasu RR .2020 .. Sample Size and Power Analysis; Chapter 13. Principles of Research Design and Drug Literature Evaluation. 1, : 139-50.
Shrestha B,Dunn L .2019 .The Declaration of Helsinki on Medical Research involving Human Subjects: A Review of Seventh Revision. J Nepal Health Res Counc, 17 : 548-52.
Kim DH,Uno H,Wei L .2017 .Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiol, 2 : 1179-80.
Barratt A,Wyer PC,Hatala R .2004 .Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ, 171 : 353-8.
Aparasu RR,Allison B,Dowling TC .2020 .Chapter 04. United States: Pharma, : 33-44.
Zhou B,Lu Y,Hajifathalian K,Bentham J,Di Cesare M,Danaei G .2016 .Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants. Lancet, 387 : 1513-30.
Scherer PE,Hill JA .2016 .Obesity, diabetes, and cardiovascular diseases: a compendium. AHA, : 1703-5.
Members TF,Piepoli MF,Hoes A.. 2016 .2016 .European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). EJPC, 23 : NP1-NP96.
Zinman B,Wanner C,Lachin JM .2015 .Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM, 373 : 2117-28.
Halvorsen S,Andreotti F,Berg JM,Cattaneo M,Coccheri S,Marchioli R .2014 .Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol, 64 : 319-27.
0

Citations

0

Downloads

30

Views